UNITED STATES PATENT AND TRADEMARK OFFICE
BEFORE THE PATENT TRIAL AND APPEAL BOARD
MYLAN PHARMACEUTICALS INC.
Petitioner
v.

Patent Owner

JANSSEN ONCOLOGY, INC.

\_\_\_\_

Case No. IPR2016-01332 U.S. Patent No. 8,822,438

\_\_\_\_\_

DECLARATION OF BRYAN D. BEEL
IN SUPPORT OF MOTION FOR *PRO HAC VICE* ADMISSION OF
BRYAN D. BEEL



## I, Bryan D. Beel, declare as follows:

- 1. I am counsel in the patent litigation group at Perkins Coie LLP.
- 2. I am a member in good standing of the Bar of the State of Oregon. I am also admitted to practice before the United States Courts of Appeals for the Fourth Circuit and Federal Circuit. I am admitted to practice before the United States District Court for the District of Oregon, and the Supreme Court of Oregon.
  - 3. My State of Oregon Bar membership number is OR 073408.
- 4. I have been practicing law for more than nine years, including litigating patent cases, specifically focused on pharmaceutical patent cases, for the last seven years.
- 5. More generally, I have represented the Petitioner and/or its various related entities in litigating significant pharmaceutical patent cases, such as the following infringement cases:
  - BTG Int'l Ltd. v. Actavis Labs. FL, Inc., Civil Action No. 2:15-cv-05909-KM-JBC (U.S. District Court for the District of New Jersey);
  - AstraZeneca AB v. Mylan Laboratories Ltd., Civil Action No. 3:12-cv-01378-MLC-TJB (U.S. District Court for the District of New Jersey);
  - AstraZeneca AB v. Mylan Pharms. Inc., No. 13-cv-04022-MLC-TJB
     (U.S. District Court for the District of New Jersey);



- Horizon Pharma, Inc. v. Mylan Pharms. Inc., No. 15-cv-03327-MLC DEA (U.S. District Court for the District of New Jersey);
- Novartis AG v. Mylan Pharms. Inc., No. 16-cv-00289-LPS (U.S.
   District Court for the District of Delaware); and
- Horizon Pharma, Inc. v. Mylan Pharms. Inc., No. 16-cv-04921-MLC-DEA (U.S. District Court for the District of New Jersey).
- 6. I have never been disbarred, sanctioned or cited for contempt by any court or administrative body. I am not currently suspended in any bar or by any court or administrative body.
- 7. I have never had a court deny my application for admission to practice.
- 8. I am familiar with the subject matter of this proceeding. In addition to U.S. Patent No. 8,822,438 ("the '438 patent") and its prosecution history, I am familiar with the technology at issue and Zytiga, the pharmaceutical product for which the '438 patent is listed by Janssen in FDA's publication, *Approved Drug Products with Therapeutic Equivalence Evaluations*, commonly referred to as the "Orange Book." I have been litigating issues surrounding Zytiga for more than a year in *BTG Int'l Ltd. v. Actavis Labs. FL, Inc.*, Civil Action No. 2:15-cv-05909-KM-JBC (D.N.J.), on behalf of Mylan Pharmaceuticals and Mylan Inc.



9. In connection with my work on the Zytiga litigation, I have become familiar with the prior art references that are the subject of this proceeding.

10. Given my familiarity with the underlying facts and my litigation experience with the Federal Rules of Evidence, I have experience and expertise

important to representing Mylan's interests in this matter.

11. I have read and will comply with Office Patent Trial Practice guide

and the Board's Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R.

12. I agree to be subject to the United States Patent and Trademark Office

Code of Professional Responsibility set forth in 37 C.F.R.§§ 11.101 et. seq. and

disciplinary jurisdiction under 37 C.F.R. § 11.19(a).

13. I have not previously applied for admission *pro hac vice* before the

United States Patent and Trademark Office.

14. I hereby declare that all statements made herein of my own

knowledge are true and that all statements made on information and belief are

believed to be true; and further that these statements are made with the knowledge

that willful false statements and the like are punishable by fine, imprisonment, or

both, under Section 1001 of Title 18 of the United States Code.

Dated: January 25, 2017

/s/ Bryan D. Beel

Bryan D. Beel

